{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:14:13Z","timestamp":1792080853739,"version":"4.4.0"},"reference-count":39,"publisher":"SAABRON PRESS","issue":"4","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Waldenstrom\u2019s macroglobulinemia (WM) or lymphoplasmacytic lymphoma is a B-cell malignancy characterized by lymphoplasmacytic cells in the bone marrow that secrete high amounts of immunoglobulin (Ig) M. The large pentameric structure of IgM leads to a variety of unique complications in WM, such as hyperviscosity syndrome, cryoglobulinemia and sensory neuropathy. Furthermore, malignant cells can infiltrate the central nervous system and lead to a variety of neurological complications, also known as Bing Neel Syndrome. Because of the unique pathophysiology of WM and these complications, their diagnostic work up and treatment regimens vary greatly. Given the rarity of the disease and their complications, there are little to no randomized controlled trials regarding treatments of these complications and, therefore, suggested treatment regimens are usually based on observational studies. In this case series, we will present three cases of WM, each with their own unique complication, and discuss the pathophysiology along with current and future treatment options for each of the complications presented.<\/jats:p>","DOI":"10.46989\/001c.124268","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T10:40:53Z","timestamp":1728297653000},"source":"Crossref","is-referenced-by-count":3,"title":["Pathophysiology and Treatments of Complications of Waldenstr\u00f6m\u2019s Macroglobulinemia"],"prefix":"10.46989","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5047-2776","authenticated-orcid":false,"given":"Nikhil","family":"Patel","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02pttbw34","id-type":"ROR","asserted-by":"publisher"}],"name":"Baylor College of Medicine","department":["Internal Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-8042","authenticated-orcid":false,"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/005k4dn45","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Arkansas Medical Center","department":["Myeloma Institute"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3262-8949","authenticated-orcid":false,"given":"Sarvari","family":"Yellapragada","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02pttbw34","id-type":"ROR","asserted-by":"publisher"}],"name":"Baylor College of Medicine","department":["Hematology"]},{"id":[{"id":"https:\/\/ror.org\/052qqbc08","id-type":"ROR","asserted-by":"publisher"}],"name":"Michael E. DeBakey VA Medical Center","department":["Hematology"]},{"id":[{"id":"https:\/\/ror.org\/02nre0x31","id-type":"ROR","asserted-by":"publisher"}],"name":"Dan L Duncan Comprehensive Cancer Center","department":["Hematology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"ref1","article-title":"Immunity against Cancer","journal-title":"Encyclop\u00e6dia Britannica"},{"issue":"3","key":"ref2","doi-asserted-by":"publisher","first-page":"e228376","DOI":"10.1136\/bcr-2018-228376","article-title":"Waldenstrom-associated anti-MAG paraprotein polyneuropathy with neurogenic tremor","volume":"12","author":"C. Canepa","year":"2019","journal-title":"BMJ Case Rep"},{"issue":"3","key":"ref3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3324\/haematol.2009.017251","article-title":"Pathophysiology of Waldenstr\u00f6m's macroglobulinemia","volume":"95","author":"M. J. Stone","year":"2010","journal-title":"Haematologica"},{"key":"ref4","article-title":"Waldenstr\u00f6m Macroglobulinemia: Possible Effects","author":"S. Meister","year":"2022","journal-title":"The Waiting Room"},{"issue":"13","key":"ref5","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1182\/blood-2018-06-846816","article-title":"Acute hyperviscosity: syndromes and management","volume":"132","author":"Morie A. Gertz","year":"2018","journal-title":"Blood"},{"key":"ref6","series-title":"StatPearls [Internet]","article-title":"Hyperviscosity Syndrome. [Updated 2023 Mar 13]","author":"A. Perez Rogers","year":"2023"},{"issue":"23","key":"ref7","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1182\/blood.2019000725","article-title":"How I treat Waldenstr\u00f6m macroglobulinemia","volume":"134","author":"Meletios A. Dimopoulos","year":"2019","journal-title":"Blood"},{"issue":"1","key":"ref8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/bjh.14196","article-title":"Recommendations for the diagnosis and initial evaluation of patients with Waldenstr\u00f6m Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenstr\u00f6m Macroglobulinaemia","volume":"175","author":"J. J. Castillo","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"ref9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1182\/asheducation-2016.1.226","article-title":"Cold agglutinin disease","volume":"2016","author":"Sigbj\u00f8rn Berentsen","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"ref10","doi-asserted-by":"publisher","first-page":"e240242","DOI":"10.1136\/bcr-2020-240242","article-title":"IgM paraprotein and anti-MAG sensory polyneuropathy associated with Waldenstrom's macroglobulinaemia and medullary carcinoma of the thyroid","volume":"14","author":"Y. Yang","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"5","key":"ref11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clml.2017.02.028","article-title":"Waldenstr\u00f6m Macroglobulinemia: Review of Pathogenesis and Management","volume":"17","author":"S. Yun","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"ref12","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3390\/hemato3040051","article-title":"Bing\u2013Neel Syndrome: Update on Diagnosis and Treatment","volume":"3","author":"E. Y. Wong","year":"2022","journal-title":"Hemato"},{"issue":"3","key":"ref13","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.1016\/j.clml.2021.09.014","article-title":"Bing-Neel Syndrome: Update on the Diagnosis and Treatment","volume":"22","author":"A. Nanah","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"ref14","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.3324\/haematol.2015.133744","article-title":"Bing-Neel syndrome, a rare complication of Waldenstr\u00f6m macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO)","volume":"100","author":"L. Simon","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"ref15","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/ana.21577","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy","volume":"65","author":"M. C. Dalakas","year":"2009","journal-title":"Ann Neurol"},{"issue":"12","key":"ref16","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.3324\/haematol.2013.087213","article-title":"Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients","volume":"98","author":"M. A. Hospital","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"ref17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/jnc.15021","article-title":"Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen-specific glycopolymer","volume":"154","author":"B. Aliu","year":"2020","journal-title":"J Neurochem"},{"issue":"1","key":"ref18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3324\/haematol.2016.147728","article-title":"Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome","volume":"102","author":"M. C. Minnema","year":"2017","journal-title":"Haematologica"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/bjh.16167","article-title":"How we manage Bing\u2013Neel syndrome","volume":"187","author":"J. J. Castillo","year":"2019","journal-title":"Br J Haematol"},{"issue":"9","key":"ref20","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3324\/haematol.2022.280953","article-title":"IgM monoclonal gammopathies of clinical significance: diagnosis and management","volume":"107","author":"J. Khwaja","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"ref21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1182\/blood-2016-09-719773","article-title":"How I treat cryoglobulinemia","volume":"129","author":"Eli Muchtar","year":"2017","journal-title":"Blood"},{"issue":"11","key":"ref22","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Z. R. Hunter","year":"2014","journal-title":"Blood"},{"issue":"4","key":"ref23","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/blood-2018-10-879593","article-title":"Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study","volume":"133","author":"J. J. Castillo","year":"2019","journal-title":"Blood"},{"key":"ref24","article-title":"Understanding the Cryoglobulinemias - Scientific Figure on ResearchGate"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"300605","DOI":"10.1016\/j.hpr.2022.300605","article-title":"Type 2 mixed monoclonal IGM and polyclonal IGG cryoglobulinemia can be associated with concurrent renal and intestinal thrombosis: Case report","volume":"27","author":"S. Kumar","year":"2022","journal-title":"Human Pathology Reports"},{"issue":"5","key":"ref26","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1055\/s-2003-44555","article-title":"Hyperviscosity syndrome in cryoglobulinemia: clinical aspects and therapeutic considerations","volume":"29","author":"A. Della Rossa","year":"2003","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"ref27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1182\/blood-2016-09-719773","article-title":"How I treat cryoglobulinemia","volume":"129","author":"Eli Muchtar","year":"2017","journal-title":"Blood"},{"issue":"10","key":"ref28","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1182\/blood-2016-04-711234","article-title":"Treatment recommendations from the Eighth International Workshop on Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"128","author":"V\u00e9ronique Leblond","year":"2016","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jha2.686","article-title":"Ibrutinib response in a patient with refractory mixed essential cryoglobulinemia","volume":"2023","author":"H. Jamali","journal-title":"eJHaem"},{"issue":"2","key":"ref30","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ajh.26796","article-title":"Waldenstr\u00f6m macroglobulinemia: 2023 update on diagnosis, risk stratification, and management","volume":"98","author":"M. A. Gertz","year":"2023","journal-title":"Am J Hematol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e2100380","DOI":"10.1200\/GO.21.00380","article-title":"Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study","volume":"8","author":"E. Riva","year":"2022","journal-title":"JCO Glob Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41375-022-01732-9","article-title":"Managing Waldenstr\u00f6m\u2019s macroglobulinemia with BTK inhibitors","volume":"37","author":"C. Buske","year":"2023","journal-title":"Leukemia"},{"issue":"6","key":"ref33","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMc1506192","article-title":"MYD88 Mutations and Response to Ibrutinib in Waldenstr\u00f6m's Macroglobulinemia","volume":"373","author":"S.P. Treon","year":"2015","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"5183646","DOI":"10.1155\/2017\/5183646","article-title":"Utility of MYD88 in the Differential Diagnosis and Choice of Second-Line Therapy in a Case of Nonsecretory Lymphoplasmacytic Lymphoma versus Free Light Chain Waldenstrom's Macroglobulinemia","volume":"2017","author":"D. Kazmierski","year":"2017","journal-title":"Case Rep Hematol"},{"issue":"22","key":"ref35","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1182\/blood-2013-04-494849","article-title":"A new era for Waldenstrom macroglobulinemia: MYD88 L265P","volume":"121","author":"S.P. Treon","year":"2013","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41375-022-01732-9","article-title":"Managing Waldenstr\u00f6m\u2019s macroglobulinemia with BTK inhibitors","volume":"37","author":"C. Buske","year":"2023","journal-title":"Leukemia"},{"issue":"6","key":"ref37","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","article-title":"Bruton Tyrosine Kinase Inhibitors: Present and Future","volume":"25","author":"J. A. Burger","year":"2019","journal-title":"Cancer J"},{"issue":"4","key":"ref38","doi-asserted-by":"publisher","first-page":"381","DOI":"10.6004\/jadpro.2020.11.4.5","article-title":"Waldenstr\u00f6m Macroglobulinemia: Clinical Presentation, Diagnosis, and Management","volume":"11","author":"M. Hobbs","year":"2020","journal-title":"J Adv Pract Oncol"},{"issue":"11","key":"ref39","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1002\/ajh.25254","article-title":"Predictors of symptomatic hyperviscosity in Waldenstr\u00f6m macroglobulinemia","volume":"93","author":"J. P. Abeykoon","year":"2018","journal-title":"Am J Hematol"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/124268-pathophysiology-and-treatments-of-complications-of-waldenstrom-s-macroglobulinemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:41:38Z","timestamp":1784734898000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/124268-pathophysiology-and-treatments-of-complications-of-waldenstrom-s-macroglobulinemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.124268","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,7]]}}}